Related Experiment Video

Updated: May 12, 2026

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
05:18

Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells

Published on: June 9, 2020

RNA interference in the treatment of colon cancer

Jose Prados1, Consolacion Melguizo, Hector Roldan

  • 1Institute of Biopathology and Regenerative Medicine, University of Granada, Spain.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|April 5, 2013
PubMed

Insights

RNA interference (RNAi) offers a promising, low-toxicity approach to combat rising colorectal cancer rates by silencing oncogenes. This review explores RNAi

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Colorectal cancer is a leading cause of cancer death, with increasing incidence over two decades.
  • Conventional chemotherapy for colorectal cancer presents significant limitations.
  • Genetic and epigenetic alterations drive colon cancer, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To review the current knowledge and application of RNA interference (RNAi) techniques in colon cancer treatment.
  • To explore RNAi as a specific and potent therapeutic strategy with low toxicity.
  • To highlight the potential of RNAi in silencing deregulated oncogenes in colon cancer.

Main Methods:

  • Literature review of studies utilizing RNA interference (RNAi) for colon cancer treatment.
  • Analysis of RNAi mechanisms, including gene silencing of oncogenes.
  • Examination of vector-based delivery systems (adenovirus, lentivirus) in preclinical models.

Main Results:

  • RNA interference demonstrates high specificity and potency in targeting and silencing oncogenes implicated in colon cancer.
  • Preclinical studies show the potential of RNAi in cancer research and treatment development.
  • Technical challenges in clinical translation, particularly vector delivery, remain significant.

Conclusions:

  • RNA interference represents a novel therapeutic avenue for colon cancer, offering advantages over traditional chemotherapy.
  • Further research is needed to overcome delivery challenges and facilitate clinical application of RNAi.
  • RNAi technology provides valuable insights into colon cancer pathogenesis and treatment strategies.

More Related Videos

Intestinal Epithelial Regeneration in Response to Ionizing Irradiation09:10

Intestinal Epithelial Regeneration in Response to Ionizing Irradiation

Published on: July 27, 2022

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...